JPM: Verve Therapeutics unveils its lead program—a one-and-done treatment for genetic high cholesterol

Verve Therapeutics debuted nearly two years ago with $58.5 million and a goal to bring one-and-done gene editing treatments to heart disease. Now, the company is marching toward the clinic with a treatment for a genetic form of high cholesterol.